DEBRA
Phase 3 Recruiting
1,670 enrolled
CAMBRIA-1
Phase 3 Recruiting
4,300 enrolled
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
Phase 2 Recruiting
80 enrolled
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
Phase 2 Recruiting
200 enrolled
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
Phase 2 Recruiting
66 enrolled
ELEGANT
Phase 3 Recruiting
4,220 enrolled
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer
Phase 3 Recruiting
4,800 enrolled
POWER II
Phase 3 Recruiting
354 enrolled
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
Phase 2 Recruiting
74 enrolled
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
Phase 3 Recruiting
1,903 enrolled
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
Phase 2 Recruiting
20 enrolled
BabyTears
Phase 2 Recruiting
140 enrolled
MAPPER
Phase 2 Recruiting
100 enrolled
AURA
Phase 3 Recruiting
290 enrolled
TREAT ctDNA
Phase 3 Recruiting
220 enrolled
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Phase 2 Recruiting
50 enrolled
CAMBRIA-2
Phase 3 Recruiting
5,500 enrolled
CAMERAN
Phase 2 Recruiting
90 enrolled
TALES
Phase 3 Recruiting
309 enrolled
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Phase 3 Recruiting
766 enrolled
Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer
Phase 3 Recruiting
1,946 enrolled
Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients
Phase 3 Recruiting
688 enrolled
HORNEO01
Phase 2 Recruiting
262 enrolled